Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FGFR Inhibitors for Advanced Cholangiocarcinoma

April 12th 2021

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.

Promoting the Importance of Molecular Testing in CCA

April 12th 2021

The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.

FDA Authorizes Marketing of First AI Device to Detect Signs of Colon Cancer

April 12th 2021

The FDA has authorized the marketing of the first device that utilizes artificial intelligence based on machine learning to help clinicians detect lesions like polyps or suspected tumors in the colon in real time during a colonoscopy.

Seribantumab Induces Tumor Regression in NRG1 Fusion+ GI Cancer Mouse Models

April 11th 2021

Seribantumab demonstrated efficacy in reducing tumor growth in preclinical models of NRG1 fusion–positive gastrointestinal cancers, suggesting that the use of seribantumab as monotherapy could have clinical utility in treating patients with GI and other NRG1 fusion–driven cancers.

Nivolumab/Paclitaxel Combo Shows Antitumor Activity in EBV-Related, MSI-H, PD-L1+ Advanced Gastric Cancer

April 10th 2021

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.

Zenocutuzumab Demonstrates Efficacy in Blocking Growth of NRG1 Fusion–Driven Tumors

April 10th 2021

Zenocutuzumab has been shown to block the growth and cause the death of NRG1 fusion–positive cell lines, and to induce tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.

Trastuzumab Deruxtecan Shows Sensitivity in Various Levels of HER2-Expressing Gastric Cancer Cells

April 10th 2021

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

Saif Shares Key Treatment Considerations for Advanced Pancreatic Cancer

April 9th 2021

Wasif Saif, MD, discusses factors to consider when choosing a frontline treatment strategy in pancreatic cancer, highlights the hunt for helpful biomarkers of response to available options, and offers sequencing suggestions.

Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCC

April 9th 2021

Anna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.

Final Thoughts on the Future of Liver Cancer

April 8th 2021

A panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.

Clinical Benefit of Ripretinib Expands as Investigators Consider Future Directions

April 8th 2021

Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.

Nivolumab-Based Combos Show Superior Survival Benefit Over Chemo in Unresectable Advanced or Metastatic ESCC

April 8th 2021

The combination of nivolumab and ipilimumab and nivolumab plus chemotherapy resulted in a statistically significant overall survival benefit compared with chemotherapy alone in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.

CELESTIAL and RESORCE Trials in HCC

April 7th 2021

Amit Singal, MD, comments on the use of cabozantinib in patients with Child-Pugh A and Child-Pugh B disease as well as regorafenib in advanced stage HCC (hepatocellular carcinoma).

Role of VEGF TKIs for Second-Line Therapy in HCC

April 7th 2021

Considerations for selecting a VEGF TKI (tyrosine kinase inhibitor) in the second-line setting for the management of HCC (hepatocellular carcinoma).

Dr. Ghidini on the Effects of Body Weight Loss in Gastric/GEJ Cancer

April 6th 2021

Michele Ghidini, MD, PhD, discusses the effects of body weight loss in gastric/gastroesophageal junction cancer.

Updated Data Confirm Clinical Benefit of Novel Immunotherapy Combos in HCC

April 6th 2021

Daniel Lin, MD, MS, highlights pivotal trials evaluating immunotherapy regimens in patients with hepatocellular carcinoma, remaining sequencing questions, and emerging regimens that are showing promise.

ctDNA Scratches the Surface in Colorectal Cancer

April 5th 2021

Axel Grothey, MD, discusses the potential applications for ctDNA in CRC and shed light on the updated analysis from the pivotal IMbrave150 trial in advanced hepatocellular carcinoma.

Immunotherapy Agents Demonstrate Groundbreaking Data in GI Cancers

April 5th 2021

Lakshmi Rajdev, MD, discusses some of the key developments made with immunotherapy in GI cancers and the groundbreaking data that have recently read out to support their use.

Advanced Cholangiocarcinoma: Molecular Testing

April 5th 2021

Experts who treat patients with GI cancers, such as cholangiocarcinoma, emphasize the need for more standardized approaches to molecular testing.

Advanced Cholangiocarcinoma: Transition to Precision Medicine

April 5th 2021

A panel of GI oncologists comment on the transition to targeted therapy and immunotherapy as treatments for advanced cholangiocarcinoma, as well as highlight predictive and prognostic markers that can help guide treatment decisions with novel therapies.